<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02510547</url>
  </required_header>
  <id_info>
    <org_study_id>15-010</org_study_id>
    <nct_id>NCT02510547</nct_id>
  </id_info>
  <brief_title>Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the &quot;CrossBoss First&quot; Trial</brief_title>
  <official_title>Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the &quot;CrossBoss First&quot; Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Texas Veterans Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Henry Ford Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Central Heart-Avera Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saint Lukes Hospital Mid America Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Missouri Heart Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deborah Heart and Lung Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Minneapolis Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellspan Heart and Vascular</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United Heart and Vascular Clinic and United Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>North Texas Veterans Healthcare System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CrossBoss First is a single-blind randomized controlled trial that will randomize 246
      patients undergoing clinically-indicated Chronic Total Occlusion Percutaneous Coronary
      Intervention, to upfront use of the CrossBoss catheter vs. antegrade guidewire escalation
      strategy The &quot;CrossBoss First&quot; study has two primary objectives. The primary efficacy
      objective is to compare the procedure time required to cross the CTO or abort the procedure
      with a CrossBoss first vs. antegrade wire escalation strategy. The investigators hypothesize
      that upfront use of the CrossBoss catheter will be associated with shorter procedure time
      required for CTO crossing compared with an antegrade wire escalation strategy.

      The primary safety objective is to compare the frequency of procedural major adverse
      cardiovascular events (MACE) with upfront use of CrossBoss vs. a guidewire escalation
      strategy. The investigators hypothesize that upfront use of the CrossBoss catheter will be
      associated with similar incidence of MACE compared with an antegrade wire escalation
      strategy.

      The secondary endpoints are: (1) technical and procedural success4-6; (2) total procedure
      time (defined as the interval between administration of local anesthesia for obtaining
      vascular access and removal of the last catheter); (3) fluoroscopy time to cross the CTO and
      total fluoroscopy time; (4) total air kerma radiation exposure; (5) total contrast volume;
      and (6) number of wires, microcatheters, balloons, and stents used.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiovascular Events</measure>
    <time_frame>Until Hospital Discharge (usually 1 day after procedure)</time_frame>
    <description>Incidence of procedural major adverse cardiovascular events (MACE, composite death, emergent coronary artery bypass graft surgery, tamponade requiring pericardiocentesis, and stroke)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure time to Cross the CTO</measure>
    <time_frame>Until end of procedure (usually 2-3 hours after procedure starts)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical and procedural success</measure>
    <time_frame>Until end of procedure (usually 2-3 hours after procedure starts)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total procedure time</measure>
    <time_frame>Until end of procedure (usually 2-3 hours after procedure starts)</time_frame>
    <description>Interval between administration of local anesthesia for obtaining vascular access and removal of the last catheter)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy time to cross CTO and total fluoroscopy time</measure>
    <time_frame>Until end of procedure (usually 2-3 hours after procedure starts)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total air kerma radiation exposure</measure>
    <time_frame>Until end of procedure (usually 2-3 hours after procedure starts)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total contrast volume</measure>
    <time_frame>Until end of procedure (usually 2-3 hours after procedure starts)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of wires, microcatheters balloons and stents used.</measure>
    <time_frame>Until end of procedure (usually 2-3 hours after procedure starts)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">246</enrollment>
  <condition>Arteriosclerosis</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>CrossBoss Catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Crossing the CTO with upfront use of the CrossBoss catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antegrade Wire Escalation Strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Crossing the CTO with upfront antegrade wire escalation strategy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CrossBoss Catheter</intervention_name>
    <description>Upfront use of the CrossBoss catheter for CTO lesion crossing</description>
    <arm_group_label>CrossBoss Catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Antegrade Wire Escalation Strategy</intervention_name>
    <description>Upfront guidewire escalation strategy for CTO lesion crossing</description>
    <arm_group_label>Antegrade Wire Escalation Strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or greater

          -  Willing and able to give informed consent

          -  Undergoing clinically-indicated CTO PCI with a planned antegrade crossing approach

        Exclusion Criteria:

          -  Plan for primary retrograde approach for CTO crossing

          -  Ostial CTOs (within 5 mm of vessel ostium)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanouil S Brilakis, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>North Texas Veterans Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Heart and Vascular Clinic and United Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missouri Heart Center</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Mid America Heart Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deborah Heart and Lung Center</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellspan Heart and Vascular</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Central Heart/Avera Heart Hospital</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA North Texas Healthcare System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Michael TT, Papayannis AC, Banerjee S, Brilakis ES. Subintimal dissection/reentry strategies in coronary chronic total occlusion interventions. Circ Cardiovasc Interv. 2012 Oct;5(5):729-38. doi: 10.1161/CIRCINTERVENTIONS.112.969808. Review.</citation>
    <PMID>23074346</PMID>
  </reference>
  <reference>
    <citation>Wosik J, Shorrock D, Christopoulos G, Kotsia A, Rangan BV, Roesle M, Maragkoydakis S, Abdullah SM, Banerjee S, Brilakis ES. Systematic Review of the BridgePoint System for Crossing Coronary and Peripheral Chronic Total Occlusions. J Invasive Cardiol. 2015 Jun;27(6):269-76. Review.</citation>
    <PMID>26028653</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2015</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>North Texas Veterans Healthcare System</investigator_affiliation>
    <investigator_full_name>Emmanouil Brilakis</investigator_full_name>
    <investigator_title>Emmanouil Brilakis, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

